Acute toxicity study of a simian immunodeficiency virus-based lentiviral vector for retinal gene transfer in nonhuman primates

Yasuhiro Ikeda, Yoshikazu Yonemitsu, Masanori Miyazaki, Ri Ichiro Kohno, yusuke murakami, Toshinori Murata, Yoshinobu Goto, Toshiaki Tabata, Yasuji Ueda, Fumiko Ono, Toshimichi Suzuki, Naohide Ageyama, Keiji Terao, Mamoru Hasegawa, Katsuo Sueishi, Tatsuro Ishibashi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A phase 1 clinical trial evaluating the safety of gene therapy for patients with wet age-related macular degeneration (AMD) or retinoblastoma has been completed without problems. The efficacy of gene therapy for Leber's congenital amaurosis (LCA) was reported by three groups. Gene therapy may thus hold promise as a therapeutic method for the treatment of intractable ocular diseases. However, it will first be important to precisely evaluate the efficiency and safety of alternative gene transfer vectors in a preclinical study using large animals. In the present study, we evaluated the acute local (ophthalmic) and systemic toxicity of our simian immunodeficiency virus from African green monkeys (SIVagm)-based lentiviral vectors carrying human pigment epithelium-derived factor (SIV-hPEDF) for transferring genes into nonhuman primate retinas. Transient inflammation and elevation of intraocular pressure were observed in some animals, but these effects were not dose dependent. Electroretinograms (ERGs), including multifocal ERGs, revealed no remarkable change in retinal function. Histopathologically, SIV-hPEDF administration resulted in a certain degree of inflammatory reaction and no apparent structural destruction in retinal tissue. Regarding systemic toxicity, none of the animals died, and none showed any serious side effects during the experimental course. No vector leakage was detected in serum or urine samples. We thus propose that SIVagm-mediated stable gene transfer might be useful and safe for ocular gene transfer in a clinical setting.

Original languageEnglish
Pages (from-to)943-954
Number of pages12
JournalHuman Gene Therapy
Volume20
Issue number9
DOIs
Publication statusPublished - Sep 1 2009

Fingerprint

Simian Immunodeficiency Virus
Primates
Genetic Therapy
Cercopithecus aethiops
Genes
Leber Congenital Amaurosis
Safety
Clinical Trials, Phase I
Retinoblastoma
Eye Diseases
Macular Degeneration
Intraocular Pressure
Retina
Urine
Inflammation
Therapeutics
Serum
pigment epithelium-derived factor

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Acute toxicity study of a simian immunodeficiency virus-based lentiviral vector for retinal gene transfer in nonhuman primates. / Ikeda, Yasuhiro; Yonemitsu, Yoshikazu; Miyazaki, Masanori; Kohno, Ri Ichiro; murakami, yusuke; Murata, Toshinori; Goto, Yoshinobu; Tabata, Toshiaki; Ueda, Yasuji; Ono, Fumiko; Suzuki, Toshimichi; Ageyama, Naohide; Terao, Keiji; Hasegawa, Mamoru; Sueishi, Katsuo; Ishibashi, Tatsuro.

In: Human Gene Therapy, Vol. 20, No. 9, 01.09.2009, p. 943-954.

Research output: Contribution to journalArticle

Ikeda, Y, Yonemitsu, Y, Miyazaki, M, Kohno, RI, murakami, Y, Murata, T, Goto, Y, Tabata, T, Ueda, Y, Ono, F, Suzuki, T, Ageyama, N, Terao, K, Hasegawa, M, Sueishi, K & Ishibashi, T 2009, 'Acute toxicity study of a simian immunodeficiency virus-based lentiviral vector for retinal gene transfer in nonhuman primates', Human Gene Therapy, vol. 20, no. 9, pp. 943-954. https://doi.org/10.1089/hum.2009.048
Ikeda, Yasuhiro ; Yonemitsu, Yoshikazu ; Miyazaki, Masanori ; Kohno, Ri Ichiro ; murakami, yusuke ; Murata, Toshinori ; Goto, Yoshinobu ; Tabata, Toshiaki ; Ueda, Yasuji ; Ono, Fumiko ; Suzuki, Toshimichi ; Ageyama, Naohide ; Terao, Keiji ; Hasegawa, Mamoru ; Sueishi, Katsuo ; Ishibashi, Tatsuro. / Acute toxicity study of a simian immunodeficiency virus-based lentiviral vector for retinal gene transfer in nonhuman primates. In: Human Gene Therapy. 2009 ; Vol. 20, No. 9. pp. 943-954.
@article{4cb31b2afa8f4ba1974b91071093d492,
title = "Acute toxicity study of a simian immunodeficiency virus-based lentiviral vector for retinal gene transfer in nonhuman primates",
abstract = "A phase 1 clinical trial evaluating the safety of gene therapy for patients with wet age-related macular degeneration (AMD) or retinoblastoma has been completed without problems. The efficacy of gene therapy for Leber's congenital amaurosis (LCA) was reported by three groups. Gene therapy may thus hold promise as a therapeutic method for the treatment of intractable ocular diseases. However, it will first be important to precisely evaluate the efficiency and safety of alternative gene transfer vectors in a preclinical study using large animals. In the present study, we evaluated the acute local (ophthalmic) and systemic toxicity of our simian immunodeficiency virus from African green monkeys (SIVagm)-based lentiviral vectors carrying human pigment epithelium-derived factor (SIV-hPEDF) for transferring genes into nonhuman primate retinas. Transient inflammation and elevation of intraocular pressure were observed in some animals, but these effects were not dose dependent. Electroretinograms (ERGs), including multifocal ERGs, revealed no remarkable change in retinal function. Histopathologically, SIV-hPEDF administration resulted in a certain degree of inflammatory reaction and no apparent structural destruction in retinal tissue. Regarding systemic toxicity, none of the animals died, and none showed any serious side effects during the experimental course. No vector leakage was detected in serum or urine samples. We thus propose that SIVagm-mediated stable gene transfer might be useful and safe for ocular gene transfer in a clinical setting.",
author = "Yasuhiro Ikeda and Yoshikazu Yonemitsu and Masanori Miyazaki and Kohno, {Ri Ichiro} and yusuke murakami and Toshinori Murata and Yoshinobu Goto and Toshiaki Tabata and Yasuji Ueda and Fumiko Ono and Toshimichi Suzuki and Naohide Ageyama and Keiji Terao and Mamoru Hasegawa and Katsuo Sueishi and Tatsuro Ishibashi",
year = "2009",
month = "9",
day = "1",
doi = "10.1089/hum.2009.048",
language = "English",
volume = "20",
pages = "943--954",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Acute toxicity study of a simian immunodeficiency virus-based lentiviral vector for retinal gene transfer in nonhuman primates

AU - Ikeda, Yasuhiro

AU - Yonemitsu, Yoshikazu

AU - Miyazaki, Masanori

AU - Kohno, Ri Ichiro

AU - murakami, yusuke

AU - Murata, Toshinori

AU - Goto, Yoshinobu

AU - Tabata, Toshiaki

AU - Ueda, Yasuji

AU - Ono, Fumiko

AU - Suzuki, Toshimichi

AU - Ageyama, Naohide

AU - Terao, Keiji

AU - Hasegawa, Mamoru

AU - Sueishi, Katsuo

AU - Ishibashi, Tatsuro

PY - 2009/9/1

Y1 - 2009/9/1

N2 - A phase 1 clinical trial evaluating the safety of gene therapy for patients with wet age-related macular degeneration (AMD) or retinoblastoma has been completed without problems. The efficacy of gene therapy for Leber's congenital amaurosis (LCA) was reported by three groups. Gene therapy may thus hold promise as a therapeutic method for the treatment of intractable ocular diseases. However, it will first be important to precisely evaluate the efficiency and safety of alternative gene transfer vectors in a preclinical study using large animals. In the present study, we evaluated the acute local (ophthalmic) and systemic toxicity of our simian immunodeficiency virus from African green monkeys (SIVagm)-based lentiviral vectors carrying human pigment epithelium-derived factor (SIV-hPEDF) for transferring genes into nonhuman primate retinas. Transient inflammation and elevation of intraocular pressure were observed in some animals, but these effects were not dose dependent. Electroretinograms (ERGs), including multifocal ERGs, revealed no remarkable change in retinal function. Histopathologically, SIV-hPEDF administration resulted in a certain degree of inflammatory reaction and no apparent structural destruction in retinal tissue. Regarding systemic toxicity, none of the animals died, and none showed any serious side effects during the experimental course. No vector leakage was detected in serum or urine samples. We thus propose that SIVagm-mediated stable gene transfer might be useful and safe for ocular gene transfer in a clinical setting.

AB - A phase 1 clinical trial evaluating the safety of gene therapy for patients with wet age-related macular degeneration (AMD) or retinoblastoma has been completed without problems. The efficacy of gene therapy for Leber's congenital amaurosis (LCA) was reported by three groups. Gene therapy may thus hold promise as a therapeutic method for the treatment of intractable ocular diseases. However, it will first be important to precisely evaluate the efficiency and safety of alternative gene transfer vectors in a preclinical study using large animals. In the present study, we evaluated the acute local (ophthalmic) and systemic toxicity of our simian immunodeficiency virus from African green monkeys (SIVagm)-based lentiviral vectors carrying human pigment epithelium-derived factor (SIV-hPEDF) for transferring genes into nonhuman primate retinas. Transient inflammation and elevation of intraocular pressure were observed in some animals, but these effects were not dose dependent. Electroretinograms (ERGs), including multifocal ERGs, revealed no remarkable change in retinal function. Histopathologically, SIV-hPEDF administration resulted in a certain degree of inflammatory reaction and no apparent structural destruction in retinal tissue. Regarding systemic toxicity, none of the animals died, and none showed any serious side effects during the experimental course. No vector leakage was detected in serum or urine samples. We thus propose that SIVagm-mediated stable gene transfer might be useful and safe for ocular gene transfer in a clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=70349131216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349131216&partnerID=8YFLogxK

U2 - 10.1089/hum.2009.048

DO - 10.1089/hum.2009.048

M3 - Article

VL - 20

SP - 943

EP - 954

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 9

ER -